LobbyingAmbiopharm lobbying by quarter
Ambiopharm's latest lobbying report covers Q2 2026, at $80K. Its first report covers Q2 2026; the issues it reports most are Pharmacy and Taxation/Internal Revenue Code.
Ambiopharm
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $80K
- Last 2 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2026 | $80K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$26.7K · 1 reports
- Taxation$26.7K · 1 reports
- Trade$26.7K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES1 reports
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Thorn Run Partners | $80K | 1 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | Thorn Run Partners | $80K |
| 05/12for Q2 | Thorn Run Partners | Under $5,000 |